October 2022 Content Release Copied

10/27/20222022 ContentContent releasePhysician, Clinical, Admin, Billing

Clinical Profile Documentation

AJCC Version 9 Staging

This release contains updated TNM values, Staging Groups, and Template functionality to align with AJCC version 9 conditions for:

  • Anal Cancer

Users will see updated values and descriptions for Primary Tumor Type (T), Regional Lymph Nodes (N), and Distance Metastasis (M), documentation points for Anal cancer.

The following value is no longer available:

  • Tis

The following documentation points now have updated descriptions:

  • T1, T2, and T3
  • N0, T1, N1a, N1b, and N1c
  • pM1

The staging calculator will display updated Stage values based on the changes to the staging groups. The new content does not affect previous charting documented on existing patients. A summary table is provided below.

All previous charting is brought forward during a subsequent visit, just as it did prior to this release.

Tumor Type Node Metastasis Stage
T1 N0 M0 I
T2 N0 M0 IIA
T1-T2 N1 M0 IIB
T3 N0-N1 M0 IIIA
T4 N0 M0 IIIB
T4 N1 M0 IIIC
Any T Any N M1 IV

Problem Groups

Additions

The Problems > Add Details area is updated with applicable documentation points for the following diagnoses.

BRAF mutation is now available for Biliary tract cancers (Gallbladder, Intrahepatic, extrahepatic distal, and Extrahepatic perihilar) with the following documentation points:

  • BRAF V600E (Mutated)
  • Wild-type
  • Mutations
  • Unknown

RET gene mutation is now available for Biliary tract cancers (Gallbladder, Intrahepatic, extrahepatic distal, and Extrahepatic perihilar) with the following documentation points:

  • RET fusion positive
  • RET fusion negative
  • Ordered: Result pending
  • Not performed
  • Unknown

Updates

Hepatocellular carcinoma (HCC), Gallbladder and Bile duct cancers have been assigned a pathway (PW) designation to ensure documentation remains synonymous with clinical decision support and ICD-10 mapping.

The following problems now have PW to the left of the problem in the search results:

  • Primary carcinoma of liver (disorder)
  • Liver cell carcinoma (disorder)
  • Malignant neoplasm of liver (disorder)
  • Primary malignant neoplasm of liver (disorder)
  • Local recurrence of malignant tumor of liver (disorder)
  • Fibrolamellar hepatocellular carcinoma (disorder)
  • Pediatric hepatocellular carcinoma (disorder)
  • Metastasis from malignant tumor of liver (disorder)
  • Primary fibrolamellar hepatocellular carcinoma (disorder)
  • Primary liver cell carcinoma (disorder)
  • Primary combined hepatocellular carcinoma and cholangiocarcinoma (disorder)
  • Adult hepatocellular carcinoma (disorder)
  • Carcinoma in situ of liver (disorder)
  • Malignant neoplasm of intrahepatic gall duct (disorder)
  • Primary cystadenocarcinoma of intrahepatic bile duct (disorder)
  • Malignant neoplasm of interlobular bile ducts (disorder)
  • Malignant neoplasm of intrahepatic canaliculi (disorder)
  • Klatskin’s tumor (disorder)
  • Primary malignant neoplasm of intrahepatic bile duct (disorder)
  • Primary malignant neoplasm of perihilar bile duct (disorder)
  • Primary malignant neoplasm of distal bile duct (disorder)
  • Intrahepatic bile duct carcinoma (disorder)
  • Carcinoma in situ of intrahepatic bile ducts (disorder)
  • Carcinoma common bile duct (disorder)
  • Carcinoma in situ of common hepatic duct (disorder)
  • Primary cholangiocarcinoma of intrahepatic biliary tract (disorder)
  • Cholangiocarcinoma of perihilar bile duct (disorder)
  • Primary adenocarcinoma of intrahepatic bile duct (disorder)
  • Carcinoma in situ of common bile duct (disorder)
  • Carcinoma of gallbladder (disorder)

Problems

  • Primary malignant neoplasm of gallbladder (disorder)
  • Malignant tumor of gallbladder (disorder)
  • Primary adenocarcinoma of gallbladder (disorder)
  • Local recurrence of malignant tumor of gallbladder (disorder)
  • Primary neuroendocrine carcinoma of gallbladder (disorder)
  • Metastasis from malignant tumor of gallbladder (disorder)
  • Adenocarcinoma of gallbladder and extrahepatic biliary tract (disorder)
  • Squamous cell carcinoma of gallbladder and extrahepatic biliary tract (disorder)
  • Malignant mesenchymal neoplasm of gallbladder (disorder)
  • Carcinoma of gallbladder and extrahepatic biliary tract (disorder)
  • Carcinoma in situ of gallbladder (disorder)

Additions

New items are available for documentation in Problems and appear in the Charge Capture Report (CCR). Additional ICD-10 codes* may be displayed to present the surrounding nodes. Please see APPENDIX A for a complete summary of changes.

Lab Analytes & Panels

Additions

  • ANCA-MPO Ab
  • ANCA-PR3 Ab
  • Anion Gap POCT ISTAT
  • Antithrombin III antigen, % normal
  • Bacterial vaginosis by TMA
  • Candida glabrata by TMA
  • Candida species (other) by TMA
  • CD4 count and % panel
  • Chronic 10 color flow cytometry lymphoproliferative panel
  • Chronic 10 color panel result
  • CML chromosome/FISH profile cells analyzed I
  • CML chromosome/FISH profile cells analyzed II
  • CML chromosome/FISH profile cells counted I
  • CML chromosome/FISH profile cells counted II
  • CML chromosome/FISH profile cells karyotyped
  • CML chromosome/FISH profile cytogenetic result
  • CML chromosome/FISH profile director review I
  • CML chromosome/FISH profile director review II
  • CML Chromosome/FISH profile FISH result
  • CML chromosome/FISH profile GTG band resolution achieved
  • CML chromosome/FISH profile interpretation I
  • CML chromosome/FISH profile interpretation II
  • CML Chromosome/FISH profile panel
  • CML chromosome/FISH profile PDF
  • CML chromosome/FISH profile specimen type I
  • CML chromosome/FISH profile specimen type II
  • Guardant Reveal results
  • Guardant360 CDx result
  • Guardant360 Response panel
  • Guardant360 Response result
  • Guardant360 TissueNext panel
  • Guardant360 TissueNext result
  • Hepatitis B surface total ab panel
  • HIV 1/2 ab/ag 4th generation panel
  • HIV ab/ag 4th generation panel
  • Invitae hereditary paraganglioma- pheochromocytoma panel + preliminary- evidence genes for hereditary paraganglioma- pheochromocytoma
  • Invitae hereditary paraganglioma- pheochromocytoma panel + preliminary- evidence genes for hereditary paraganglioma- pheochromocytoma results
  • JAK2/MPL/CALR by NGS rflx detailed genetic interpretation I
  • JAK2/MPL/CALR by NGS rflx interpretation summary
  • JAK2/MPL/CALR by NGS rflx methods
  • JAK2/MPL/CALR by NGS rflx panel
  • JAK2/MPL/CALR by NGS rflx references I
  • JAK2/MPL/CALR by NGS rflx report footer
  • JAK2/MPL/CALR by NGS rflx technical summary
  • KIT D816V background
  • KIT D816V director review
  • KIT D816V method
  • KIT D816V quantitative value
  • KIT D816V references
  • KIT D816V result
  • KIT D816V specimen type
  • Myeloperoxidase (MPO) IgG Ab
  • Myeloperoxidase IgG Ab panel
  • OnkoSight advanced NGS myeloid detailed genetic interpretation 1
  • OnkoSight advanced NGS myeloid interpretation summary
  • OnkoSight advanced NGS myeloid methods
  • OnkoSight advanced NGS myeloid panel
  • OnkoSight advanced NGS myeloid panel result
  • OnkoSight advanced NGS myeloid report footer
  • OnkoSight advanced NGS myeloid technical summary
  • OnkoSight MPN panel
  • Parvovirus B19 DNA PCR, qual
  • PD-L1 IHC, FDA atezolizumab (SP142) result
  • PD-L1 IHC, FDA nivolumab w/ ipilimumab (28-8) result
  • PD-L1 IHC, FDA pembrolizumab or biosimilar (22C3) result
  • Pharyngeal gonorrhea/chlamydia by PCR panel
  • Proteinase-3 AUTO Abs panel
  • Proteinase-3 AUTO Abs, quant
  • Rectal gonorrhea/chlamydia by PCR panel
  • Syphilis Ab, IgG IgM panel
  • Trichomonas vaginalis by TMA
  • Troponin I, ug/L
  • Vaginal panel by TMA

Medications

Additions

  • ATRN-119 invest Oral
  • CDX-1140 invest IV
  • CDX-301 invest Subcutaneous
  • E7386 invest Oral
  • MRT-2359 invest Oral

Updates

Medication Update
Carfilzomib IV New Dose and Unit available:

  • 70 mg/m2
Dexamethasone IV New default Sig available:

  • 10 mg intravenously once
Granisetron IV New default Sig available:

  • 1 mg intravenously once
Imm glob G (IgG)-Sorb-IgA 0-50 (PF) IV New Max single dose available:

  • 300000 mg

New default Sig available:

  • 300 mg/kg intravenously Piggyback once

New dose Unit available:

  • mg

New Instructions available:

  • 5% Product: Initiate at a rate of 0.01 mL/kg/minute (0.5 mg/kg/minute) for 30 minutes. If tolerated, may gradually increase rate to a maximum of 0.10 mL/kg/minute (5 mg/kg/minute). 10% Product: Initiate at a rate of 0.01 mL/kg/minute (1 mg/kg/minute) for 30 minutes. If tolerated, may gradually increase rate to a maximum of 0.08 mL/kg/minute (8 mg/kg/minute).
Immun Glob G (IgG)-Gly-IgA 50+ (PF) IV New Max single dose available:

  • 360000 mg

New default Sig available:

  • 300 mg/kg intravenously Piggyback once New dose Unit available:
  • mg

New Instructions available:

  • Initiate at a rate of 0.5 mL/kg/hour (0.8 mg/kg/minute) for 30 minutes. If tolerated, may gradually increase rate every 30 minutes to a maximum of 5 mL/kg/hour (8 mg/kg/minute).
Immun glob G(IgG)-Malt-IgA 50+ (PF) IV 10 % New Max single dose available:

  • 300000 mg

New default Sig available:

  • 300 mg/kg intravenously Piggyback once

New dose Unit available:

  • mg

New Instructions available:

  • Initiate at a rate of 60 mg/kg/hour for 30 minutes. If tolerated, increase rate to 120 mg/kg/hour for 30 minutes. If tolerated, increase rate to 240 mg/kg/hour for 30 minutes. If tolerated, increase rate to 480 mg/kg/hour for 30 minutes. If further tolerated, increase rate up to a maximum of 720 mg/kg/hour thereafter.
Immun glob G(IgG)-Malt-IgA 50+ (PF) IV 5 % New Max single dose available:

  • 300000 mg

New default Sig available:

  • 300 mg/kg intravenously Piggyback once New dose Unit available:
  • Mg

New Instructions available:

  • Initiate at a rate of 30 mg/kg/hour for the 30 minutes. If tolerated, increase rate to 60 mg/kg/hour for 30 minutes. If tolerated, increase rate to 120 mg/kg/hour for 30 minutes. If further tolerated, increase rate up to a maximum of 200 mg/kg/hour thereafter.
Immun glob G(IgG)-Pro-IgA 0-50 (PF) IV New Max single dose available:

  • 300000 mg

New default Sig available:

  • 200 mg/kg intravenously Piggyback once New Dose Unit available:
  • mg

New Instructions available:

  • Initiate at a rate of 0.005 mL/kg/minute (0.5 mg/kg/minute). If tolerated, may gradually increase rate to a maximum rate which varies based on indication. Maximum rate for PI and CIDP is 0.08 mL/kg/min (8 mg/kg/minute). Maximum rate for ITP is 0.04 mL/kg/min (4 mg/kg/min).
Immune glob G (IgG)-Gly-IgA avg 46 (PF) IV (Gammaked) New Max single dose available:

  • 300000 mg

New default Sig available:

  • 300 mg/kg intravenously Piggyback once

New Dose Unit available:

  • mg

New Instructions available:

  • Initiate at a rate of 0.01 mL/kg/minute (1 mg/kg/minute). If tolerated, may increase rate gradually to a maximum of 0.08 mL/kg/minute (8 mg/kg/minute).
Immune glob G (IgG)-Gly-IgA avg 46 (PF) IV (Gamunex-C) New Max single dose available:

  • 300000 mg

New default Sig available:

  • 300 mg/kg intravenously Piggyback once

New Dose Unit available:

  • mg

New Instructions available:

  • Initiate at a rate of 0.01 mL/kg/minute (1 mg/kg/minute). If tolerated, may increase rate gradually to a maximum of 0.08 mL/kg/minute (8 mg/kg/minute).
Immune globulin, Gamma(IgG)-ifas IV New Max single dose available:

  • 300000 mg

New default Sig available:

  • 300 mg/kg intravenously Piggyback once

New Dose Unit available:

  • mg

New Instructions available:

  • Initiate at a rate of 0.01 mL/kg/minute (1 mg/kg/minute) for 30 minutes. If tolerated, may gradually increase rate every 15-30 minutes to a maximum rate which varies based on indication. Max rate for PI is 0.14 mL/kg/minute (14 mg/kg/minute). Max rate for ITP is 0.08 mL/kg/minute (8 mg/kg/minute). Max rate for CIDP is 0.12 mL/kg/minute (12 mg/kg/minute).
ON 123300 invest Oral New Form available:

  • 60 mg capsule
Palonosetron IV New default Sig available:

  • 0.25 mg intravenously once
RGX-202-01 invest Oral New Form available:

  • 600 mg tablet
Siremadlin invest Oral New Form available:

  • 30 mg capsule
Tisotumab vedotin-tftv IV New Max single dose available:

  • 200 mg

Regimen Library

Biosimilar and Reference Regimens

To improve ease of ordering, the Collaborative Care Committee (CCC) recently voted to merge separate biosimilar and reference regimens into single regimen templates. These updates will occur in a rolling fashion over the next several months.

This release contains the consolidation of all rituximab regimen templates. For a list of all merged rituximab regimens please refer to APPENDIX B.

Additions

Regimen Name Diagnosis
Carfilzomib D1,2,15,16 + Lenalidomide D1-21 Q28D (Post-Transplant Maintenance) Multiple Myeloma (MM)
Capecitabine (665 mg/m2) + XRT Q35D (Bile Duct) Bile Duct Cancer (Parent); Gallbladder Cancer
Fluorouracil (Bolus + CIV) D1-2 + Leucovorin D1-2 + Oxaliplatin (FOLFOX 4) Q14D Bile Duct Cancer (Parent); Gallbladder Cancer
Fluorouracil Bolus D1-5 + Leucovorin D1-5 Q21D (Bile Duct) Bile Duct Cancer (Parent); Gallbladder Cancer
Gemcitabine D1,8 + Oxaliplatin Q21D (Bile Duct) Bile Duct Cancer (Parent); Gallbladder Cancer
Gemcitabine D1,8 + Capecitabine (750 mg/m2) D1-14 Q21D (Bile Duct) Bile Duct Cancer (Parent); Gallbladder Cancer
Gemcitabine D1,8 + Cisplatin Q21D (Bile Duct) Bile Duct Cancer (Parent); Gallbladder Cancer
Nivolumab + Ifosfamide CIV D2 + Carboplatin D2 + Etoposide D1-3 (ICE) Q21D Lymphoma, Hodgkin (HL)

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

  • Anemia, Hemolytic, Autoimmune (Parent)
  • Arthritis, Rheumatoid
  • Fallopian Tube Cancer
  • Gastric Cancer
  • Leukemia, Chronic Lymphocytic (CLL)
  • Leukemia, Hairy Cell
  • Lung Cancer, Non-small Cell (NSCLC)
  • Lymphoma, Hodgkin (HL)
  • Lymphoma, Non-Hodgkin (NHL) (Parent)
  • Mycosis Fungoides/Sezary Syndrome
  • Primary Cutaneous Lymphoma
  • Sarcoma, Soft Tissue (Parent)
  • Solid Tumors (Parent) (including Solid Other/HL)
  • Thyroid Cancer (Parent)
  • Waldenstrom’s Macroglobulinemia

Renames

Previous Name New Name
Fluorouracil Bolus D1-3,29-31 + XRT Q42D Fluorouracil Bolus D1-3,29-31 + XRT Q35D (Bile Duct)
Lenalidomide D1-21 Q28D (NHL) Lenalidomide D1-21 Q28D (NHL, MM)
Pemigatinib Q21D Pemigatinib Q21D (Bile Duct)
Topotecan D1-5 Q21D Topotecan IV D1-5 Q21D
Trastuzumab IV + Pertuzumab IV Q21D (Colon, Rectal) Trastuzumab IV + Pertuzumab IV Q21D (Colon, Rectal, Bile Duct)

Research

Updates

Updated Reference Information Updated Drug Service Order Information Updated Regimen Instructions Other Changes
USOR 17160 X X X
USOR 19043 X X X
USOR 19151 X X X Now available:

  • USOR 19151 MRTX849 (PO; BID) Q21D
  • USOR 18283 Zimberelimab Q21D

No longer available:

  • USOR 19151 MRTX849 600 mg BID
  • USOR 19151 MRTX849 400 mg BID
USOR 20248 X X Now available:

  • USOR 20248 Open-Label Extension Niraparib/Abiraterone + Prednisone
USOR 20249 X X X
USOR 20336 X X X
USOR 21183 X
USOR 21225 X X X
USOR 21234 X X Now available:

  • USOR 21234 Post-Study Extension Enobosarm (PO; Daily)
USOR 21253 X
USOR 21273 X X X
USOR 21281 X X X
USOR 21287 X
USOR 21308 X X X Now available:

  • USOR 21308 ZN-c3 (PO; Intermittent 5:2) + Niraparib (PO; Daily) Q28D
USOR 21320 X X
USOR 21411 X X Now available:

  • USOR 21411 Cohort A Avelumab Continuation Q14D USOR 21411 Cohort B Trastuzumab Continuation Q7D USOR 21411 Cohort B Trastuzumab Continuation Q21D USOR 21411 Cohort C Cetuximab Continuation Q7D USOR 21411 Cohort C Cetuximab Continuation Q14D USOR 21411 Cohort D Pembrolizumab Continuation Q21D USOR 21411 Cohort D Pembrolizumab Continuation Q42D USOR 21411 Cohort D Nivolumab Continuation Q14D USOR 21411 Cohort D Nivolumab Continuation Q28D USOR 21411 Cohort D Atezolizumab Continuation Q14D USOR 21411 Cohort D Atezolizumab Continuation Q21D USOR 21411 Cohort D Atezolizumab Continuation Q28D USOR 21411 Tocilizumab for CRS

No longer available:

  • USOR 21411 Cohort B Conditioning CY/FLU + Trastuzumab BIOSIMILAR (QW) + FT538
  • USOR 21411 Cohort B Conditioning CY/FLU + Trastuzumab BIOSIMILAR (Q3W) + FT538
USOR 21412 X X Now available:

  • USOR 21412 Tocilizumab for CRS
USOR 21459 X
USOR 21485 X X Now available:

  • USOR 21485 Tocilizumab for CRS

No longer available:

  • USOR 21485 Regimen B1 Conditioning CY/FLU D-5,-4,-3 + Rituximab IV D-4 Reference
  • USOR 21485 Regimen B1 Conditioning CY/FLU D-5,-4,-3 + Rituximab IV BIOSIMILAR D-4
USOR 22018 X
USOR 22074 X X X

Billing & HCPCS Codes

Updates

Medication HCPCS Codes
Sodium Thiosulfate (Pedmark) J3490 per 12.5 gram
Eflapegrastim-xnst (Rolvedon) J3490 per 13.2 mg
Elivaldogene Autotemcel (Skysona) J3590 per 5x 10e6CD34+ cells/kg
Flortaucipir F-18 (Tauvid) A9601 per: 1 mCi

37 MBq
Pegfilgrastim-pbbk (Fylnetra) J3590 per 6 mg
Ranibizumab-eqrn Intravitreal J3590 per 6 mg
Vutrisiran (Amvuttra) J3490 per 25 mg

Appendix A

Problem & Codes Summary

Additions

Problem ICD-10 Codes
Abnormal findings on diagnostic imaging of other abdominal regions, including retroperitoneum R93.5 Abnormal findings on diagnostic imaging of other abdominal regions, including retroperitoneum
Abscess of breast associated with lactation (disorder) O91.13 Abscess of breast associated with lactation
Acquired dilation of bile duct (disorder) K83.8 Other specified diseases of biliary tract
Acute hypoxemic respiratory failure (disorder) J96.01 – Acute respiratory failure with hypoxia
Acute oophoritis (disorder) N70.02 Acute oophoritis
Acute pneumothorax (disorder) J93.83 Other pneumothorax
Acute post-thoracotomy pain G89.12 Acute post-thoracotomy pain
Acute respiratory disease (disorder) J06.9 Acute upper respiratory infection, unspecified
Acute salpingitis (disorder) N70.01 Acute salpingitis
Acute salpingo-oophoritis (disorder) N70.03 Acute salpingitis and oophoritis
Acute uterine inflammatory disease (disorder) N71.0 Acute inflammatory disease of uterus
Adhesion of bile duct (disorder) K83.8 Other specified diseases of biliary tract
Aftercare following surgery for neoplasm Z48.3 Aftercare following surgery for neoplasm
Anal ectropion (disorder) K62.89 Other specified diseases of anus and rectum
Anal pain (finding) K62.89 Other specified diseases of anus and rectum
Anemia due to antineoplastic chemotherapy D64.81 – Anemia due to antineoplastic chemotherapy
Anorectal pain (finding) K62.89 Other specified diseases of anus and rectum
Antineutrophilic cytoplasmic antibody [ANCA] vasculitis I77.2 Antineutrophilic cytoplasmic antibody [ANCA] vasculitis
Atrophy of bile duct (disorder) K83.8 Other specified diseases of biliary tract
Benign lipomatous neoplasm of other sites D17.79 Benign lipomatous neoplasm of other sites
Benign lipomatous neoplasm of skin and/or subcutaneous tissue of bilateral upper limbs (disorder) D17.21 Benign lipomatous neoplasm of skin and subcutaneous tissue of right arm D17.22 Benign lipomatous neoplasm of skin and subcutaneous tissue of left arm
Benign lipomatous neoplasm of skin and/or subcutaneous tissue of bilateral lower limbs (disorder) D17.23 Benign lipomatous neoplasm of skin and subcutaneous tissue of right leg D17.24 Benign lipomatous neoplasm of skin and subcutaneous tissue of left leg
Benign lipomatous neoplasm, skin AND/OR subcutaneous tissue of left upper limb (disorder) D17.22 Benign lipomatous neoplasm of skin and subcutaneous tissue of left arm
Benign lipomatous neoplasm, skin AND/OR subcutaneous tissue of left lower limb (disorder) D17.24 Benign lipomatous neoplasm of skin and subcutaneous tissue of left leg
Benign lipomatous neoplasm, skin AND/OR subcutaneous tissue of right upper limb (disorder) D17.21 Benign lipomatous neoplasm of skin and subcutaneous tissue of right arm
Benign lipomatous neoplasm, skin AND/OR subcutaneous tissue of right lower limb (disorder) D17.23 Benign lipomatous neoplasm of skin and subcutaneous tissue of right leg
Benign neoplasm of bone and articular cartilage D16.9 Benign neoplasm of bone and articular cartilage, unspecified
Benign neoplasm of left bronchus and lung D14.32 Benign neoplasm of left bronchus and lung
Benign neoplasm of long bones of lower limb (disorder) D16.20 Benign neoplasm of long bones of unspecified lower limb

D16.21 Benign neoplasm of long bones of right lower limb

D16.22 Benign neoplasm of long bones of left lower limb
Benign neoplasm of right bronchus and lung D14.31 Benign neoplasm of right bronchus and lung
Benign neoplasm of soft tissue of lower leg (disorder) D21.20 Benign neoplasm of connective and other soft tissue of unspecified lower limb, including hip

D21.21 Benign neoplasm of connective and other soft tissue of right lower limb, including hip

D21.22 Benign neoplasm of connective and other soft tissue of left lower limb, including hip
Benign neoplasm of soft tissues of lower limb (disorder) D21.20 Benign neoplasm of connective and other soft tissue of unspecified lower limb, including hip

D21.21 Benign neoplasm of connective and other soft tissue of right lower limb, including hip

D21.22 Benign neoplasm of connective and other soft tissue of left lower limb, including hip
Benign neoplasm of unspecified bronchus and lung D14.30 Benign neoplasm of unspecified bronchus and lung
Burkitt lymphoma, extranodal and solid organ sites C83.79 Burkitt lymphoma, extranodal and solid organ sites
Caregiver’s intentional underdosing of medication regimen for other reason Z91.A28 Caregiver’s intentional underdosing of medication regimen for other reason
Caregiver’s intentional underdosing of patient’s medication regimen due to financial hardship Z91.A20 Caregiver’s intentional underdosing of patient’s medication regimen due to financial hardship
Caregiver’s noncompliance with patient’s dietary regimen due to financial hardship Z91.A10 Caregiver’s noncompliance with patient’s dietary regimen due to financial hardship
Caregiver’s noncompliance with patient’s dietary regimen for other reason Z91.A18 Caregiver’s noncompliance with patient’s dietary regimen for other reason
Caregiver’s noncompliance with patient’s other medical treatment and regimen Z91.A9 Caregiver’s noncompliance with patient’s other medical treatment and regimen
Caregiver’s noncompliance with patient’s renal dialysis Z91.A5 Caregiver’s noncompliance with patient’s renal dialysis
Caregiver’s other noncompliance with patient’s medication regimen Z91.A4 Caregiver’s other noncompliance with patient’s medication regimen
Caregiver’s unintentional underdosing of patient’s medication regimen Z91.A3 Caregiver’s unintentional underdosing of patient’s medication regimen
Catamenial pneumothorax (disorder) J93.83 Other pneumothorax
Celiac artery compression syndrome (disorder) I77.4 – Celiac artery compression syndrome
CHEK2 mutation Z15.01 Genetic susceptibility to malignant neoplasm of breast

Z15.89 Genetic susceptibility to other disease
Chronic lymphocytic leukemia of B-cell type not having achieved remission C91.10 Chronic lymphocytic leukemia of B-cell type not having achieved remission
Chronic osteomyelitis of left lower leg with draining sinus (disorder) M86.462 Chronic osteomyelitis with draining sinus, left tibia and fibula
Chronic osteomyelitis of lower leg with draining sinus (disorder) M86.469 Chronic osteomyelitis with draining sinus, unspecified tibia and fibula
Chronic osteomyelitis of right lower leg with draining sinus (disorder) M86.461 Chronic osteomyelitis with draining sinus, right tibia and fibula
Chronic pneumothorax (disorder) J93.81 Chronic pneumothorax
Chronic post-COVID-19 syndrome (disorder) B97.89 Other viral agents as the cause of diseases classified elsewhere

Z86.16 Personal history of COVID-19
Chronic uterine inflammatory disease (disorder) N71.1 Chronic inflammatory disease of uterus
Clicking pneumothorax (disorder) J93.9 Pneumothorax, unspecified
Congenital arteriovenous malformation of left lower limb Q27.32 Arteriovenous malformation of vessel of lower limb

Q27.32 Arteriovenous malformation of vessel of lower limb
Congenital cystic disease of liver (disorder) Q44.6 – Cystic disease of liver
COVID-19 U07.1 COVID-19
Cyst (disorder) L72.9 Follicular cyst of the skin and subcutaneous tissue, unspecified
Deep endometriosis of bilateral fallopian tubes N80.223 Deep endometriosis of bilateral fallopian tubes
Deep endometriosis of bilateral ovaries N80.123 Deep endometriosis of bilateral ovaries
Deep endometriosis of left fallopian tube N80.222 Deep endometriosis of left fallopian tube
Deep endometriosis of left ovary N80.122 Deep endometriosis of left ovary
Deep endometriosis of right fallopian tube N80.221 Deep endometriosis of right fallopian tube
Deep endometriosis of right ovary N80.121 Deep endometriosis of right ovary
Deep endometriosis of the anterior cul-de- sac N80.319 Endometriosis of the anterior cul-de- sac, unspecified depth
Deep endometriosis of the posterior cul- de-sac N80.322 Deep endometriosis of the posterior cul-de-sac
Deep endometriosis of unspecified fallopian tube N80.229 Deep endometriosis of unspecified fallopian tube
Deep endometriosis of unspecified ovary N80.129 Deep endometriosis of ovary, unspecified ovary
Disorder of diaphragm (disorder) J98.6 Disorders of diaphragm
Disorder of lower respiratory system (disorder) J98.9 Respiratory disorder, unspecified
Disorder of pleura AND/OR pleural cavity (disorder) J94.9 Pleural condition, unspecified
Diverticulitis of small intestine without perforation or abscess with bleeding K57.13 Diverticulitis of small intestine without perforation or abscess with bleeding
Dysfunction of sphincter of Oddi (disorder) K83.8 Other specified diseases of biliary tract
Dysplasia of vulva (disorder) N90.3 Dysplasia of vulva, unspecified
Encounter for gynecological examination (general) (routine) with abnormal findings Z01.411 Encounter for gynecological examination (general) (routine) with abnormal findings
Encounter for initial prescription of intrauterine contraceptive device Z30.014 Encounter for initial prescription of intrauterine contraceptive device
Encounter for nonprocreative genetic counseling Z71.83 Encounter for nonprocreative genetic counseling
Encounter for other general counseling and advice on contraception Z30.09 Encounter for other general counseling and advice on contraception
Encounter for other preprocedural examination Z01.818 Encounter for other preprocedural examination
Encounter for prophylactic measures Z29.9 Encounter for prophylactic measures, unspecified
Encounter for removal and reinsertion of intrauterine contraceptive device Z30.433 Encounter for removal and reinsertion of intrauterine contraceptive device
Encounter for routine checking of intrauterine contraceptive device Z30.431 Encounter for routine checking of intrauterine contraceptive device
Encounter for screening for infections with a predominantly sexual mode of transmission Z11.3 Encounter for screening for infections with a predominantly sexual mode of transmission
Encounter for surgical aftercare following surgery on the genitourinary system Z48.816 Encounter for surgical aftercare following surgery on the genitourinary system
Encounter for surveillance of other contraceptives Z30.49 Encounter for surveillance of other contraceptives
Encounter for surveillance of other contraceptives Z30.49 Encounter for surveillance of other contraceptives
Endometriosis (disorder) N80.9 Endometriosis, unspecified
Endometriosis in cutaneous scar N80.6 Endometriosis in cutaneous scar
Endometriosis of bladder (disorder) N80.A0 Endometriosis of bladder, unspecified depth

N80.A1 Superficial endometriosis of bladder N80.A2 Deep endometriosis of bladder
Endometriosis of cardiothoracic space N80.B6 Endometriosis of cardiothoracic space
Endometriosis of diaphragm N80.B31 Superficial endometriosis of diaphragm

N80.B32 Deep endometriosis of diaphragm N80.B39 Endometriosis of diaphragm, unspecified depth
Endometriosis of fallopian tube (disorder) N80.201 Endometriosis of right fallopian tube, unspecified depth

N80.202 Endometriosis of left fallopian tube, unspecified depth

N80.203 Endometriosis of bilateral fallopian tubes, unspecified depth

N80.209 Endometriosis of unspecified fallopian tube, unspecified depth
Endometriosis of intestine (disorder) N80.50 Endometriosis of intestine, unspecified
Endometriosis of left ovary (disorder) N80.102 Endometriosis of left ovary, unspecified depth
Endometriosis of lung (disorder) N80.B2 Endometriosis of lung
Endometriosis of myometrium (disorder) N80.00 Endometriosis of the uterus, unspecified

N80.01 Superficial endometriosis of the uterus N80.02 Deep endometriosis of the uterus N80.03 Adenomyosis of the uterus
Endometriosis of other parts of the colon N80.551 Superficial endometriosis of other parts of the colon

N80.552 Deep endometriosis of other parts of the colon
Endometriosis of ovary (disorder) N80.101 Endometriosis of right ovary, unspecified depth

N80.102 Endometriosis of left ovary, unspecified depth

N80.103 Endometriosis of bilateral ovaries, unspecified depth

N80.109 Endometriosis of ovary, unspecified side, unspecified depth
Endometriosis of pelvic peritoneum (disorder) N80.30 Endometriosis of pelvic peritoneum, unspecified
Endometriosis of rectovaginal septum without involvement of vagina N80.41 Endometriosis of rectovaginal septum without involvement of vagina
Endometriosis of right ovary (disorder) N80.101 Endometriosis of right ovary, unspecified depth
Endometriosis of the femoral nerve N80.D6 Endometriosis of the femoral nerve
Endometriosis of the inguinal canal N80.C3 Endometriosis of the inguinal canal
Endometriosis of the mediastinal space N80.B5 Endometriosis of the mediastinal space
Endometriosis of the obturator nerve N80.D3 Endometriosis of the obturator nerve
Endometriosis of the pelvic nerves N80.D0 Endometriosis of the pelvic nerves
Endometriosis of the pelvic sidewall N80.331 Superficial endometriosis of the right pelvic

sidewall

N80.332 Superficial endometriosis of the left pelvic sidewall

N80.333 Superficial endometriosis of bilateral pelvic sidewall

N80.339 Superficial endometriosis of pelvic sidewall, unspecified side

N80.341 Deep endometriosis of the right pelvic sidewall

N80.342 Deep endometriosis of the left pelvic sidewall

N80.343 Deep endometriosis of the bilateral pelvic sidewall

N80.349 Deep endometriosis of the pelvic sidewall, unspecified side

N80.351 Endometriosis of the right pelvic sidewall, unspecified depth

N80.352 Endometriosis of the left pelvic sidewall, unspecified depth

N80.353 Endometriosis of bilateral pelvic sidewall, unspecified depth

N80.359 Endometriosis of pelvic sidewall, unspecified side, unspecified depth
Endometriosis of the pericardial space N80.B4 Endometriosis of the pericardial space
Endometriosis of the posterior cul-de-sac N80.329 Endometriosis of the posterior cul-de- sac, unspecified depth
Endometriosis of the pudendal nerve N80.D5 Endometriosis of the pudendal nerve
Endometriosis of the sacral nerve roots N80.D2 Endometriosis of the sacral nerve roots
Endometriosis of the sacral splanchnic nerves N80.D1 Endometriosis of the sacral splanchnic nerves
Endometriosis of the sciatic nerve N80.D4 Endometriosis of the sciatic nerve
Endometriosis of the umbilicus N80.C2 Endometriosis of the umbilicus
Endometriosis of thorax (disorder) N80.B1 Endometriosis of pleura N80.B2 Endometriosis of lung
Endometriosis of umbilicus (disorder) N80.C2 Endometriosis of the umbilicus
Endometriosis of uterus (disorder) N80.00 Endometriosis of the uterus, unspecified

N80.01 Superficial endometriosis of the uterus N80.02 Deep endometriosis of the uterus N80.03 Adenomyosis of the uterus
Excessive and frequent menstruation with regular cycle N92.0 Excessive and frequent menstruation with regular cycle
Excessive menstruation with irregular cycle (finding) N92.1 Excessive and frequent menstruation with irregular cycle
Extramedullary plasmacytoma not having achieved remission C90.20 Extramedullary plasmacytoma not having achieved remission
Familial spontaneous pneumothorax (disorder) J93.11 Primary spontaneous pneumothorax
Family history of CHEK2 mutation Z84.81 Family history of carrier of genetic disease
Family history of PALB2 mutation Z84.81 Family history of carrier of genetic disease
Fatigue (finding) R53.82 Chronic fatigue, unspecified R53.83 Other fatigue
Fatigue due to chemotherapy (finding) R53.0 Neoplastic (malignant) related fatigue
Fibrocystic breast changes (finding) N60.11 Diffuse cystic mastopathy of right breast

N60.12 Diffuse cystic mastopathy of left breast N60.19 Diffuse cystic mastopathy of unspecified breast
Fibromatosis (disorder) M72.9 Fibroblastic disorder, unspecified
Fibrosis of mediastinum (disorder) J98.59 Other diseases of mediastinum, not elsewhere classified
Folliculitis (disorder) L73.9 Follicular disorder, unspecified
Fournier disease of vagina and vulva N76.82 Fournier disease of vagina and vulva
Galactorrhea not associated with childbirth (disorder) N64.3 Galactorrhea not associated with childbirth
Gangrene and necrosis of lung J85.0 Gangrene and necrosis of lung
Gastro-esophageal reflux disease with esophagitis, without bleeding K21.00 Gastro-esophageal reflux disease with esophagitis, without bleeding
Granuloma of rectum (disorder) K62.89 Other specified diseases of anus and rectum
Granulomatous disorder of the skin and subcutaneous tissue (disorder) L92.9 Granulomatous disorder of the skin and subcutaneous tissue, unspecified
Hepatomegaly, not elsewhere classified R16.0 Hepatomegaly, not elsewhere classified
Hernia of mediastinum (disorder) J98.59 Other diseases of mediastinum, not elsewhere classified
Hypertrophied anal papilla (disorder) K62.89 Other specified diseases of anus and rectum
Hypertrophy of biliary tract (disorder) K83.8 Other specified diseases of biliary tract
Hypogammaglobulinemia (finding) D80.1 Nonfamilial hypogammaglobulinemia
Hypo-osmolality and or hyponatremia (disorder) E87.1 Hypo-osmolality and hyponatremia
Infection following procedure (disorder) T81.40XA Infection following a procedure, unspecified, initial encounter

T81.40XD Infection following a procedure, unspecified, subsequent encounter T81.40XS Infection following a procedure, unspecified, sequela
Infection of nipple associated with lactation (disorder) O91.03 Infection of nipple associated with lactation
Inflammatory disease of the uterus (disorder) N71.9 Inflammatory disease of uterus, unspecified
Intraductal carcinoma in situ of right breast (disorder) D05.11 Intraductal carcinoma in situ of right breast
Isthmocele N85.A Isthmocele
Kaposi’s sarcoma of gastrointestinal tract (disorder) C46.4 Kaposi’s sarcoma of gastrointestinal sites
Langerhans cell histiocytosis (disorder) C96.6 Unifocal Langerhans-cell histiocytosis
Left inguinal hernia with obstruction, without gangrene, not specified as recurrent K40.30 Unilateral inguinal hernia, with obstruction, without gangrene, not specified as recurrent
Left pneumothorax (disorder) J93.9 Pneumothorax, unspecified
Leukoplakia of oral mucosa and tongue (disorder) K13.21 Leukoplakia of oral mucosa, including tongue
Liver mass (finding) R16.0 Hepatomegaly, not elsewhere classified
Localized enlarged lymph nodes (disorder) R59.0 Localized enlarged lymph nodes
Long term (current) use of alkylating agent Z79.630 Long term (current) use of alkylating agent
Long term (current) use of antimetabolite agent Z79.631 Long term (current) use of antimetabolite agent
Long term (current) use of antitumor antibiotic Z79.632 Long term (current) use of antitumor antibiotic
Long term (current) use of calcineurin inhibitor Z79.621 Long term (current) use of calcineurin inhibitor
Long term (current) use of immunomodulator Z79.61 Long term (current) use of immunomodulator
Long term (current) use of immunosuppressive biologic Z79.620 Long term (current) use of immunosuppressive biologic
Long term (current) use of inhibitors of nucleotide synthesis Z79.624 Long term (current) use of inhibitors of nucleotide synthesis
Long term (current) use of Janus kinase inhibitor Z79.622 Long term (current) use of Janus kinase inhibitor
Long term (current) use of mammalian target of rapamycin (mTOR) inhibitor Z79.633 Long term (current) use of mammalian target of rapamycin (mTOR) inhibitor
Long term (current) use of mitotic inhibitor Z79.633 Long term (current) use of mitotic inhibitor
Long term (current) use of myelosuppressive agent Z79.64 Long term (current) use of myelosuppressive agent
Long term (current) use of other immunomodulators and immunosuppressants Z79.69 Long term (current) use of other immunomodulators and immunosuppressants
Long term (current) use of topoisomerase inhibitor Z79.634 Long term (current) use of topoisomerase inhibitor
Long term (current) use of unspecified immunomodulators and immunosuppressants Z79.60 Long term (current) use of unspecified immunomodulators and immunosuppressants
Long-term (current) use of injectable non- insulin antidiabetic drugs Z79.85 Long-term (current) use of injectable non-insulin antidiabetic drugs
Malignant carcinoid tumor of the bronchus and lung C7A.090 Malignant carcinoid tumor of the bronchus and lung
Malignant carcinoid tumor of the bronchus and lung C7A.090 Malignant carcinoid tumor of the bronchus and lung
Malignant melanoma of skin (disorder) C43.9 Malignant melanoma of skin, unspecified
Malignant mesothelioma of peritoneum (disorder) C45.1 Mesothelioma of peritoneum
Malignant mesothelioma of pleura (disorder) C45.0 Mesothelioma of pleura
Malignant neoplasm of bone and articular cartilage C41.9 Malignant neoplasm of bone and articular cartilage, unspecified
Malignant neoplasm of connective and soft tissue of abdomen (disorder) C49.4 Malignant neoplasm of connective and soft tissue of abdomen
Malignant neoplasm of connective and soft tissue of thorax (disorder) C49.3 Malignant neoplasm of connective and soft tissue of thorax
Malignant neoplasm of corpus uteri, excluding isthmus (disorder) C54.9 Malignant neoplasm of corpus uteri, unspecified
Malignant neoplasm of long bone of lower leg (disorder) C40.20 Malignant neoplasm of long bones of unspecified lower limb

C40.21 Malignant neoplasm of long bones of right lower limb

C40.22 Malignant neoplasm of long bones of left lower limb
Malignant neoplasm of long bone of lower limb (disorder) C40.20 Malignant neoplasm of long bones of unspecified lower limb

C40.21 Malignant neoplasm of long bones of right lower limb

C40.22 Malignant neoplasm of long bones of left lower limb
Malignant neoplasm of overlapping sites of rectum, anus and anal canal C21.8 Malignant neoplasm of overlapping sites of rectum, anus and anal canal
Malignant neoplasm of ribs and/or sternum and/or clavicle (disorder) C41.3 Malignant neoplasm of ribs, sternum and clavicle
Malignant neoplasm of superior wall of nasopharynx (disorder) C11.0 Malignant neoplasm of superior wall of nasopharynx
Malignant neoplasm of unspecified renal pelvis C65.9 Malignant neoplasm of unspecified renal pelvis
Malignant neoplasm of upper lobe, bronchus or lung (disorder) C34.11 Malignant neoplasm of upper lobe, right bronchus or lung
Malignant tumor of anterior two-thirds of tongue – dorsal surface (disorder) C02.2 Malignant neoplasm of ventral surface of tongue
Malignant tumor of palate (disorder) C05.9 Malignant neoplasm of palate, unspecified
Malignant tumor of peritoneum (disorder) C48.2 Malignant neoplasm of peritoneum, unspecified
Malignant tumor of vestibule of mouth (disorder) C06.1 Malignant neoplasm of vestibule of mouth
Mastitis without abscess N61.0 Mastitis without abscess
Merkel cell carcinoma of ear and external auricular canal C4A.20 Merkel cell carcinoma of unspecified ear and external auricular canal

C4A.21 Merkel cell carcinoma of right ear and external auricular canal

C4A.22 Merkel cell carcinoma of left ear and external auricular canal
Merkel cell carcinoma of left ear and external auricular canal C4A.22 Merkel cell carcinoma of left ear and external auricular canal
Merkel cell carcinoma of left leg (disorder) C4A.72 Merkel cell carcinoma of left lower limb, including hip
Merkel cell carcinoma of lower limb (disorder) C4A.70 Merkel cell carcinoma of unspecified lower limb, including hip
Merkel cell carcinoma of right ear and external auricular canal C4A.21 Merkel cell carcinoma of right ear and external auricular canal
Merkel cell carcinoma of right leg (disorder) C4A.71 Merkel cell carcinoma of right lower limb, including hip
Metastatic malignant neoplasm to bone (disorder) C79.51 Secondary malignant neoplasm of bone
Metastatic malignant neoplasm to lymph node (disorder) C77.9 Secondary and unspecified malignant neoplasm of lymph node, unspecified
Metastatic malignant neoplasm to mediastinum (disorder) C78.1 Secondary malignant neoplasm of mediastinum
Morbid (severe) obesity due to excess calories E66.01 Morbid (severe) obesity due to excess calories
Multiple congenital exostosis (disorder) Q78.6 Multiple congenital exostosis
Multiple myeloma not having achieved remission C90.00 Multiple myeloma not having achieved remission
Neoplasm of uncertain behavior of acromion (disorder) D48.0 Neoplasm of uncertain behavior of acromion (disorder)
Neoplasm of uncertain behavior of connective and soft tissue (disorder) D48.1 Neoplasm of uncertain behavior of connective and other soft tissue
Neoplasm of uncertain behavior of other specified digestive organs D37.8 Neoplasm of uncertain behavior of other specified digestive organs
Neoplasm of uncertain behavior of ovary (disorder) D39.10 Neoplasm of uncertain behavior of unspecified ovary

D39.11 Neoplasm of uncertain behavior of right ovary

D39.12 Neoplasm of uncertain behavior of left ovary
Neoplasm of uncertain behavior of peripheral nerves and autonomic nervous system D48.2 Neoplasm of uncertain behavior of peripheral nerves and autonomic nervous system
Neoplasm of uncertain behavior of thyroid gland (disorder) D44.0 Neoplasm of uncertain behavior of thyroid gland
Neoplasm of unspecified behavior of digestive system D49.0 Neoplasm of unspecified behavior of digestive system
Nonpurulent mastitis associated with lactation (disorder) O91.23 Nonpurulent mastitis associated with lactation
Nutritional anemia (disorder) D53.9 Nutritional anemia, unspecified
Obstructive and reflux uropathy, unspecified N13.9 Obstructive and reflux uropathy, unspecified
Open pneumothorax (disorder) J93.83 Other pneumothorax
Osteomyelitis (disorder) M86.9 Osteomyelitis, unspecified
Osteomyelitis of cervical vertebra (disorder) M46.22 Osteomyelitis of vertebra, cervical region
Osteomyelitis of cervicothoracic vertebra (disorder) M46.23 Osteomyelitis of vertebra, cervicothoracic region
Osteomyelitis of occipitoatlantoaxial vertebra (disorder) M416.21 Osteomyelitis of vertebra, occipito- atlanto-axial region
Osteomyelitis of pelvic region (disorder) M86.9 Osteomyelitis, unspecified
Osteomyelitis of thoracic vertebra (disorder) M46.24 Osteomyelitis of vertebra, thoracic region
Osteomyelitis of thoracolumbar vertebra (disorder) M46.25 Osteomyelitis of vertebra, thoracolumbar region
Osteomyelitis of vertebra (disorder) M46.20 Osteomyelitis of vertebra, site unspecified
Osteomyelitis of vertebra, lumbosacral region M46.27 Osteomyelitis of vertebra, lumbosacral region
Other decreased white blood cell count D72.818 Other decreased white blood cell count
Other malignant neuroendocrine tumors C7A.8 Other malignant neuroendocrine tumors
Other specified complication of vascular prosthetic devices, implants and grafts T82.898A Other specified complication of vascular prosthetic devices, implants and grafts, initial encounter

T82.898D Other specified complication of vascular prosthetic devices, implants and grafts, subsequent encounter

T82.898S Other specified complication of vascular prosthetic devices, implants and grafts, sequela

C44.722 Squamous cell carcinoma of skin of right lower limb, including hip
Other specified female pelvic inflammatory diseases N73.8 Other specified female pelvic inflammatory diseases
Other specified functional intestinal disorders K59.89 Other specified functional intestinal disorders
Overlapping malignant neoplasm of lip, oral cavity and/or pharynx (disorder) C14.8 Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx
Overlapping malignant neoplasm of stomach (disorder) C16.8 Malignant neoplasm of overlapping sites of stomach
PALB2 mutation Z15.01 Genetic susceptibility to malignant neoplasm of breast

Z15.02 Genetic susceptibility to malignant neoplasm of ovary

Z15.89 Genetic susceptibility to other disease
Peripheral venous insufficiency (disorder) I87.2 Venous insufficiency (chronic) (peripheral)
Personal history of other malignant neoplasm of large intestine Z85.038 Personal history of other malignant neoplasm of large intestine
Pigmented villonodular synovitis of knee joint (disorder) M12.269 Villonodular synovitis (pigmented) unspecified knee
Pigmented villonodular synovitis of left knee (disorder) M12.262 Villonodular synovitis (pigmented) left knee
Pigmented villonodular synovitis of right knee (disorder) M12.261 Villonodular synovitis (pigmented) right knee
Pneumothorax (disorder) J93.9 Pneumothorax, unspecified
Pneumothorax ex vacuo (disorder) J93.83 Other pneumothorax
Polyp of stomach and duodenum K31.7 Polyp of stomach and duodenum
Post-acute COVID-19 (disorder) U09.9 Post COVID-19 condition, unspecified
Primary malignant neoplasm of body of uterus (disorder) C54.9 Malignant neoplasm of corpus uteri, unspecified
Primary malignant neoplasm of extrahepatic bile duct (disorder) C24.0 Malignant neoplasm of extrahepatic bile duct
Primary malignant neoplasm of left upper limb (disorder) C76.42 Malignant neoplasm of left upper limb
Primary malignant neoplasm of long bone of lower limb (disorder) C40.20 Malignant neoplasm of long bones of unspecified lower limb

C40.21 Malignant neoplasm of long bones of right lower limb

C40.22 Malignant neoplasm of long bones of left lower limb
Primary malignant neoplasm of myometrium (disorder) C54.2 Malignant neoplasm of myometrium
Primary malignant neoplasm of ribs and/or sternum and/or clavicle (disorder) C41.3 Malignant neoplasm of ribs, sternum and clavicle
Primary malignant neoplasm of right upper limb (disorder) C76.41 Malignant neoplasm of right upper limb
Primary malignant neoplasm of the peritoneum (disorder) C48.2 Malignant neoplasm of peritoneum, unspecified
Primary malignant neoplasm of unspecified site (disorder) C80.1 Malignant (primary) neoplasm, unspecified
Primary malignant neoplasm of upper limb (disorder) C76.40 Malignant neoplasm of unspecified upper limb

C76.41 Malignant neoplasm of right upper limb C76.42 Malignant neoplasm of left upper limb
Primary malignant neoplasm of vestibule of mouth (disorder) C06.1 – Malignant neoplasm of vestibule of mouth
Primary spontaneous pneumothorax (disorder) J93.11 Primary spontaneous pneumothorax
Primary squamous cell carcinoma of perianal skin (disorder) C44.520 Squamous cell carcinoma of anal skin
Proctitis (disorder) K62.89 Other specified diseases of anus and rectum
Pulmonary coccidioidomycosis (disorder) B38.0 Acute pulmonary coccidioidomycosis B38.1 Chronic pulmonary coccidioidomycosis B38.2 Pulmonary coccidioidomycosis, unspecified
Radiographic dye allergy status Z91.041 Radiographic dye allergy status
Rectal mass (finding) K62.89 Other specified diseases of anus and rectum
Retraction of mediastinum (disorder) J98.59 Other diseases of mediastinum, not elsewhere classified
Right inguinal hernia with obstruction, without gangrene, not specified as recurrent K40.30 Unilateral inguinal hernia, with obstruction, without gangrene, not specified as recurrent
Right pneumothorax (disorder) J93.9 Pneumothorax, unspecified
Salpingitis and oophoritis, unspecified N70.93 Salpingitis and oophoritis, unspecified
Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes C77.1 Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes
Secondary malignant neoplasm of kidney and renal pelvis C79.00 Secondary malignant neoplasm of kidney and renal pelvis
Secondary malignant neoplasm of large intestine and rectum C78.5 Secondary malignant neoplasm of large intestine and rectum
Secondary spontaneous pneumothorax (disorder) J93.12 Secondary spontaneous pneumothorax
Sepsis (disorder) A41.9 Sepsis, unspecified organism
Solitary bone cyst (disorder) M85.40 Solitary bone cyst, unspecified site
Spontaneous pneumothorax (disorder) J93.83 Other pneumothorax
Spontaneous tension pneumothorax (disorder) J93.0 Spontaneous tension pneumothorax
Squamous cell carcinoma of anal margin (disorder) C44.520 Squamous cell carcinoma of anal skin
Squamous cell carcinoma of skin (disorder) C44.92 Squamous cell carcinoma of skin, unspecified
Squamous cell carcinoma of skin of left lower limb, including hip C44.721 Squamous cell carcinoma of skin of left lower limb, including hip
Squamous cell carcinoma of skin of right lower limb, including hip C44.722 Squamous cell carcinoma of skin of right lower limb, including hip
Squamous cell carcinoma of skin of scalp and neck C44.42 Squamous cell carcinoma of skin of scalp and neck
Stricture of ureter co-occurrent and due to crossing vessel (disorder) N13.5 Crossing vessel and stricture of ureter without hydronephrosis
Superficial endometriosis of bilateral fallopian tubes N80.213 Superficial endometriosis of bilateral fallopian tubes
Superficial endometriosis of fallopian tube N80.219 Superficial endometriosis of unspecified fallopian tube
Superficial endometriosis of left fallopian tube N80.212 Superficial endometriosis of left fallopian tube
Superficial endometriosis of ovary (disorder) N80.111 Superficial endometriosis of right ovary

N80.112 Superficial endometriosis of left ovary N80.113 Superficial endometriosis of bilateral ovaries

N80.119 Superficial endometriosis of ovary, unspecified ovary
Superficial endometriosis of right fallopian tube N80.211 Superficial endometriosis of right fallopian tube
Superficial endometriosis of the anterior cul-de-sac N80.311 Superficial endometriosis of the anterior cul-de-sac
Superficial endometriosis of the posterior cul-de-sac N80.321 Superficial endometriosis of the posterior cul-de-sac
Suspected urinary tract infection (situation) Z11.2 Encounter for screening for other bacterial diseases
Synovial cyst of knee (disorder) M71.20 Synovial cyst of popliteal space [Baker], unspecified knee
Synovial cyst of left popliteal space (disorder) M71.22 Synovial cyst of popliteal space [Baker], left knee
Synovial cyst of right popliteal space (disorder) M71.21 Synovial cyst of popliteal space [Baker], right knee
Therapeutic drug effect (finding) Z51.81 Encounter for therapeutic drug level monitoring
Thyrotoxicosis with toxic single thyroid nodule without thyrotoxic crisis or storm E05.10 Thyrotoxicosis with toxic single thyroid nodule without thyrotoxic crisis or storm
Torsion of accessory fallopian tube (disorder) N83.521 Torsion of right fallopian tube N83.522 Torsion of left fallopian tube N83.529 Torsion of fallopian tube, unspecified side
Torsion of fallopian tube (disorder) N83.52 Torsion of fallopian tube
Torsion of left fallopian tube (disorder) N83.522 Torsion of left fallopian tube
Torsion of left ovary and ovarian pedicle N83.512 Torsion of left ovary and ovarian pedicle
Torsion of ovary (disorder) N83.519 Torsion of ovary and ovarian pedicle, unspecified side
Torsion of right fallopian tube (disorder) N83.521 Torsion of right fallopian tube
Torsion of right ovary and ovarian pedicle N83.511 Torsion of right ovary and ovarian pedicle
Transfusion-associated dyspnea (TAD) J95.87 Transfusion-associated dyspnea (TAD)
Ulcer of bile duct (disorder) K83.8 Other specified diseases of biliary tract
Unifocal Langerhans-cell histiocytosis C96.6 Unifocal Langerhans-cell histiocytosis
Unspecified severe protein-calorie malnutrition E43 Unspecified severe protein-calorie malnutrition
Vulval intraepithelial neoplasia (disorder) N90.0 Mild vulvar dysplasia N90.1 Moderate vulvar dysplasia

N90.3 Dysplasia of vulva, unspecified

Appendix B

Regimen Consolidation Summary

Additions

The following regimens have been created as part of the Reference Regimen / Biosimilar Merge initiative.

  • Bendamustine D1,2 + Rituximab IV (BR) Q28D
  • Bendamustine D1,2 + Rituximab IV Q28D (CLL Frontline: BR 90 mg/m2)
  • Bendamustine D1,2 + Rituximab IV Q28D (CLL Relapsed: BR 70 mg/m2)
  • Bortezomib + Dexamethasone + Rituximab IV (BDR) (Part 2 of 2)
  • Cladribine D1-5 fb Rituximab IV D1,8,15,22 Q28D
  • Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV (FCR) Q28D (CLL)
  • Ibrutinib + Bendamustine D1,2 + Rituximab IV Q28D
  • Ibrutinib + Rituximab IV D1,8,15,22 Q4M
  • Ibrutinib + Rituximab IV Q28D (CLL)
  • Idelalisib + Bendamustine D1,2 + Rituximab IV Q28D
  • Idelalisib + Rituximab IV Q28D
  • Lenalidomide D1-21 + Rituximab IV C1 D1,8,15,22 fb C4,6,8,10,12 Q28D (Part 1 of 2: Induction)
  • Lenalidomide D1-21 + Rituximab IV C1 D1,8,15,22 Q28D
  • Lenalidomide D1-21 + Rituximab IV C1,3,5 Q28D (Part 2 of 2: Maintenance)
  • Lenalidomide D1-21 + Rituximab IV D1,8,15,22 fb D1 Q28D
  • Polatuzumab vedotin + Bendamustine D1,2 + Rituximab IV Q21D
  • Polatuzumab vedotin + Rituximab IV + CHP Q21D (6 cycles) fb Rituximab IV Q21D (2 cycles)
  • Polatuzumab vedotin + Rituximab IV Q21D
  • Rituximab IV + CEOP Q21D
  • Rituximab IV + Chlorambucil D1-7 Q28D
  • Rituximab IV + CHOP Q21D alternating with Rituximab IV + DHAP (Cisplatin) Q21D
  • Rituximab IV + CHOP Q21D
  • Rituximab IV + CHOP Q21D (3 cycles)
  • Rituximab IV + CHOP Q21D (4 cycles) fb Rituximab IV Q21D (2 cycles)
  • Rituximab IV + CHOP Q21D (C1 split)
  • Rituximab IV + Cyclophosphamide + Pentostatin (PCR) Q21D
  • Rituximab IV + Cyclophosphamide + Vincristine + Prednisone D1-5 (R-CVP) Q21D
  • Rituximab IV + DHAP (Carboplatin) Q21D
  • Rituximab IV + DHAP (Cisplatin) Q21D
  • Rituximab IV + DHAP (Oxaliplatin) Q21D
  • Rituximab IV + EPOCH (Dose Adjusted) Q21D
  • Rituximab IV + ESHAP Q28D
  • Rituximab IV + Fludarabine D1-5 Q28D
  • Rituximab IV + GCVP Q21D
  • Rituximab IV + Gemcitabine D1,8 + Dexamethasone D1-4 + Cisplatin (R-GDP) Q21D
  • Rituximab IV + Gemcitabine D2 + Oxaliplatin D2 Q14D
  • Rituximab IV + Ifosfamide CIV D2 + Carboplatin D2 + Etoposide D1-3 (R-ICE) Q14D
  • Rituximab IV + miniCHOP Q21D
  • Rituximab IV D1,15 + Methotrexate PO Q6M
  • Rituximab IV D1,22 + Hyper CVAD/HD Methotrexate + Cytarabine Q42D
  • Rituximab IV D1,8 + Ibritumomab D8 Q12D
  • Rituximab IV D1,8,15,22 fb D1 Q56D
  • Rituximab IV D1,8,15,22 Q6M
  • Rituximab IV Maintenance Q56D
  • Rituximab IV Maintenance Q84D
  • Rituximab IV Maxi-CHOP + High Dose Cytarabine (Nordic) Q21D
  • Rituximab IV Q7D
  • Venetoclax + Rituximab IV Q28D

Removals

The following regimens have been inactivated as part of the Reference Regimen / Biosimilar Merge initiative:

  • Bendamustine D1,2 + Rituximab IV (BR) Q28D Reference
  • Bendamustine D1,2 + Rituximab IV Q28D (CLL Frontline: BR 90 mg/m2) Reference
  • Bendamustine D1,2 + Rituximab IV Q28D (CLL Relapsed: BR 70 mg/m2) Reference
  • Bortezomib + Dexamethasone + Rituximab IV (BDR) (Part 2 of 2) Reference
  • Cladribine D1-5 fb Rituximab IV D1,8,15,22 Q28D Reference
  • Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV (FCR) Q28D (CLL) Reference
  • Ibrutinib + Bendamustine D1,2 + Rituximab IV Q28D Reference
  • Ibrutinib + Rituximab IV D1,8,15,22 Q4M Reference
  • Ibrutinib + Rituximab IV Q28D (CLL) Reference
  • Idelalisib + Bendamustine D1,2 + Rituximab IV Q28D Reference
  • Idelalisib + Rituximab IV Q28D Reference
  • Lenalidomide D1-21 + Rituximab IV C1 D1,8,15,22 fb C4,6,8,10,12 Q28D (Part 1 of 2: Induction) Reference
  • Lenalidomide D1-21 + Rituximab IV C1 D1,8,15,22 Q28D Reference
  • Lenalidomide D1-21 + Rituximab IV C1,3,5 Q28D (Part 2 of 2: Maintenance) Reference
  • Lenalidomide D1-21 + Rituximab IV D1,8,15,22 fb D1 Q28D Reference
  • Polatuzumab vedotin + Bendamustine D1,2 + Rituximab IV Q21D Reference
  • Polatuzumab vedotin + Rituximab IV + CHP Q21D (6 cycles) fb Rituximab IV Q21D (2 cycles) Reference
  • Polatuzumab vedotin + Rituximab IV Q21D Reference
  • Rituximab IV + CEOP Q21D Reference
  • Rituximab IV + Chlorambucil D1-7 Q28D Reference
  • Rituximab IV + CHOP Q21D alternating with Rituximab IV + DHAP (Cisplatin) Q21D Reference
  • Rituximab IV + CHOP Q21D Reference
  • Rituximab IV + CHOP Q21D (3 cycles) Reference
  • Rituximab IV + CHOP Q21D (4 cycles) fb Rituximab IV Q21D (2 cycles) Reference
  • Rituximab IV + CHOP Q21D (C1 split) Reference
  • Rituximab IV + Cyclophosphamide + Pentostatin (PCR) Q21D Reference
  • Rituximab IV + Cyclophosphamide + Vincristine + Prednisone D1-5 (R-CVP) Q21D Reference
  • Rituximab IV + DHAP (Carboplatin) Q21D Reference
  • Rituximab IV + DHAP (Cisplatin) Q21D Reference
  • Rituximab IV + DHAP (Oxaliplatin) Q21D (MCL) Reference
  • Rituximab IV + EPOCH (Dose Adjusted) Q21D Reference
  • Rituximab IV + ESHAP Q28D Reference
  • Rituximab IV + Fludarabine D1-5 Q28D Reference
  • Rituximab IV + GCVP Q21D Reference
  • Rituximab IV + Gemcitabine D1,8 + Dexamethasone D1-4 + Cisplatin (R-GDP) Q21D Reference
  • Rituximab IV + Gemcitabine D2 + Oxaliplatin D2 Q14D Reference
  • Rituximab IV + Ifosfamide CIV D2 + Carboplatin D2 + Etoposide D1-3 (R-ICE) Q14D Reference
  • Rituximab IV + Maxi-CHOP + High Dose Cytarabine (Nordic) Q21D Reference
  • Rituximab IV + miniCHOP Q21D Reference
  • Rituximab IV D1,15 + Methotrexate PO Q6M Reference
  • Rituximab IV D1,22 + Hyper CVAD/HD Methotrexate + Cytarabine Q42D Reference
  • Rituximab IV D1,8 + Ibritumomab D8 Q12D Reference
  • Rituximab IV D1,8,15,22 fb D1 Q56D Reference
  • Rituximab IV D1,8,15,22 Q6M Reference
  • Rituximab IV Maintenance Q56D Reference
  • Rituximab IV Maintenance Q84D Reference
  • Rituximab IV Q7D Reference
  • Venetoclax + Rituximab IV Q28D Reference